These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 8363991

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Treatment of fever and neutropenia with antibiotics versus antibiotics plus intravenous gammaglobulin in childhood leukemia.
    Sumer T, Abumelha A, al-Mulhim I, al-Fadil M.
    Eur J Pediatr; 1989 Feb; 148(5):401-2. PubMed ID: 2493376
    [Abstract] [Full Text] [Related]

  • 3. Antibacterial therapy--special considerations in neutropenic patients.
    Rodriguez V, Bodey GP.
    Clin Haematol; 1976 Jun; 5(2):347-60. PubMed ID: 181192
    [No Abstract] [Full Text] [Related]

  • 4. Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure.
    Pea F, Viale P, Damiani D, Pavan F, Cristini F, Fanin R, Furlanut M.
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3550-3. PubMed ID: 16048982
    [Abstract] [Full Text] [Related]

  • 5. Empiric antimicrobial therapy in the febrile granulocytopenic patient.
    Hughes WT.
    Infect Control Hosp Epidemiol; 1990 Mar; 11(3):151-6. PubMed ID: 2179402
    [No Abstract] [Full Text] [Related]

  • 6. Lithium and granulocytopenia during induction therapy of acute myelogenous leukemia: update of an ongoing trial.
    Stein RS, Flexner JH, Graber SE.
    Adv Exp Med Biol; 1980 Mar; 127():187-97. PubMed ID: 6931477
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Application of the IDSA guidelines for the use of antimicrobial agents in neutropenic patients: impact on reducing the use of glycopeptides.
    Nucci M, Landau M, Silveira F, Spector N, Pulcheri W.
    Infect Control Hosp Epidemiol; 2001 Oct; 22(10):651-3. PubMed ID: 11776354
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparison of cefepime versus ceftriaxone-amikacin as empirical regimens for the treatment of febrile neutropenia in acute leukemia patients.
    Borbolla JR, López-Hernández MA, González-Avante M, DeDiego J, Trueba E, Alvarado ML, Jiménez RM.
    Chemotherapy; 2001 Oct; 47(5):381-4. PubMed ID: 11561142
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Systemic broad-spectrum antimicrobial prophylaxis in hematological patients after intensive antineoplastic chemotherapy.
    Verlicchi F, Ricci P, Bassi A, Benfenati D, Bandini G, Rosti G, Calori E, Borghi C, Tura S.
    Haematologica; 1990 Oct; 75(1):91-3. PubMed ID: 2338294
    [Abstract] [Full Text] [Related]

  • 19. Management of fever in neutropenic patients with acute leukemia: current role of ceftazidime plus amikacin as empiric therapy.
    Fanci R, Paci C, Martinez RL, Fabbri A, Pecile P, Leoni F, Longo G.
    J Chemother; 2000 Jun; 12(3):232-9. PubMed ID: 10877519
    [Abstract] [Full Text] [Related]

  • 20. Management in the febrile, neutropenic patient with cancer: therapeutic considerations.
    Brown AE.
    J Pediatr; 1985 Jun; 106(6):1035-42. PubMed ID: 3889253
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.